Amryt to present updates from its Epidermolysis Bullosa (“EB”) research programme at the first World Congress ‘EB2020’ dedicated to this rare skin disease

Amryt, an international biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases, is pleased to announce its participation at the inaugural Epidermolysis Bullosa World Congress (“EB2020”), being held on 19-23 January, 2020 in London.

Amryt’s EB research programme aims to develop transformative treatments to improve symptoms and potentially offer a cure for this rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment. The programme includes the largest ever global Phase 3 trial in EB, the EASE trial, which is being conducted at 55 sites in 27 countries with results expected later this year.

At EB2020, information on an investigational treatment for EB, Oleogel-S10 (AP101) will be discussed in a dedicated scientific satellite symposium. In addition, Amryt scientist Dr Lara Cutlar has been invited by the congress organisers to present a talk on non-viral gene therapy delivery mechanisms. Both events will take place on Tuesday 21 January in the main congress hall. Amryt’s Chief Medical Officer - Dr Mark Sumeray - will present on the Amryt research programme as part of the conference programme on Wednesday 22 January. Amryt is proud to be a platinum sponsor of the Congress.

Dr Joe Wiley, CEO of Amryt Pharma, commented today:

“Collaboration is central to Amryt’s culture and EB2020 presents an ideal opportunity for us to share our ideas, meet new partners and galvanise our shared vision to make a real difference for people living with EB. We have partnered with the EB community for over three years to highlight the condition and raise funds to support their research efforts, alongside the significant investment we have made in EB research at Amryt.”

Caroline Collins, EB2020 Congress Director & DEBRA UK’s Director of Research, commented today:

“We are delighted with the support for the first EB World Congress. This meeting will give guidance to professionals involved in EB, and drive forward strategies for research, regulatory, funding, and for the healthcare communities. Collaborating with industry partners, sponsors such as Amryt, healthcare professionals, and the EB Community gives us hope that people living with EB will have a much brighter future.”

EB2020 is an independent, global congress bringing together the world’s leading experts in EB research, clinical management, and the EB Community. The congress is being held in London on January 19-23, 2020. For more information please visit www.ebworldcongress.org.